Early hydrogels provided static support, which is biologically inaccurate. Advanced matrices must be dynamic, adapting to cells as they divide and differentiate. This active “conversation” between cell and matrix is critical for biomimetic results, allowing cells to remodel their environment as they would in a living organism.
The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.
The move to animal-free components in cell culture presents a major scientific hurdle, as cells did not evolve to grow in them. However, the key benefit is strategic. Synthetically-defined materials eliminate the batch-to-batch variability of animal-derived matrices, enabling the reproducibility and process control essential for industrial-scale manufacturing.
While automation is typically associated with increasing speed, its most crucial function in complex 3D cell culture is mitigating human error and process variability. For drug discovery, where inconsistent results are a major struggle, automation provides the data consistency needed for reliable outcomes, a more valuable benefit than throughput alone.
The initial goal was 3D printing tissue. However, the hydrogel's excellent processability (mixability, pumpability) was also the solution to a major bottleneck in drug discovery: automating 3D cell cultures in high-throughput screening (HTS) systems. This secondary characteristic unlocked a better, more immediate market.